Updated on 25 November 2025
Tackling antibiotic resistance using nano-poly-pharmacology
CEO at THERIOPHARM
Wavre, Belgium
About
Validated on a sepsis murin model using pan-resistant Acinetobacter baumannii.
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Similar opportunities
Project cooperation
New in vitro assay methodologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Hanne Haslene-Hox
Seinor research scientist at SINTEF Industry
Trondheim, Norway
Project cooperation
Targeted brain cancer drug development
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Jiney Jose
Senior Research Fellow at The University of Auckland
Auckland, New Zealand
Project cooperation
AI-Driven Microfluidic 3D In Vitro Platform for Multi-Tissue Crosstalk in Drug Testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
MARCO BERZANO
Research Manager and Advisor - Head of Medical Area at Università Politecnica delle Marche
Ancona, Italy